Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NN5H
|
|||
| Former ID |
DCL000599
|
|||
| Drug Name |
PF-4523655
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Age-related macular degeneration [ICD-11: 9B75.0] | Phase 2 | [1] | |
| Diabetic macular degeneration [ICD-11: 9B78] | Phase 2 | [1] | ||
| Company |
Quark Pharm; Pfizer
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | RTP801 messenger RNA (RTP801 mRNA) | Target Info | . | [1], [2], [3], [4] |
| KEGG Pathway | mTOR signaling pathway | |||
| PI3K-Akt signaling pathway | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathway Interaction Database | mTOR signaling pathway | |||
| Direct p53 effectors | ||||
| Reactome | TP53 Regulates Metabolic Genes | |||
| WikiPathways | TOR Signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2011 Pipeline of Quark Pharm. | |||
| REF 2 | DNA-damage-inducible transcript 4 (DDIT4; RTP801). SciBX 3(20); doi:10.1038/scibx.2010.629. May 20 2010 | |||
| REF 3 | Pfizer. Product Development Pipeline. March 31 2009. | |||
| REF 4 | The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther. 2006 Jul;5(7):1744-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.